UNSPSC 51183503: Etoformin

This classification denotes an anti-diabetic agent with the molecular formula C8H19N5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 630F8M4Q1D, chemically known as 1-butyl-2-ethylbiguanide but more generally known as etoformin, which bears US NIH Compound Identifier 170347. European Medicines Agency schedules etoformin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07322MIG. Most nations, for tariff and trade purposes, schedule etoformin under HS 29252900 and SITC 51482.

As of Q4 2014, ETOFORMIN remains US FDA's Preferred Term for this commodity. Etoformin bears US NLM identifiers UMLS ID C1880583 and NCI Concept Code C65589. SMILES: CCCCN=C(NCC)N=C(N)N.

UNSPSC 51183503 Etoformin is a Commodity code identifying a specific antidiabetic pharmaceutical product that state and local governments procure through cooperative purchasing agreements and multistate pharmaceutical contracting vehicles. Recent solicitation activity shows state and local buyers acquiring etoformin and related generic pharmaceuticals as components of broader multi-source generic drug procurement programs rather than as standalone line items, with purchasing coordinated through established wholesaler networks and subject to cGMP certification, DSCSA compliance, and detailed product specification requirements including NDC codes, dosage forms, and packaging configurations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of Purchase, issued a Request for Proposal in January 2026 (S1070000015802) to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local government facilities, including Oregon. The RFP closes March 26, 2026, and requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and the remaining 15 percent on administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Vendors must maintain commercial general liability insurance of at least five million dollars per occurrence, professional and network security liability of two million dollars each, and demonstrate pricing flexibility across flat-price, net-price (NF30, NF60, NF90), and WAC-minus formats. The contract term runs two years for new vendors with optional extensions, while incumbent amendments extend through June 30, 2028.